|
KMID : 0869620110280030274
|
|
Journal of Korean Society of Hospital Pharmacists
2011 Volume.28 No. 3 p.274 ~ p.278
|
|
|
Drug Use Evaluation of Voriconazole
|
|
Han Song-Yi
Kwon Jeong-Mi
Cho Yoon-Sook
Park Kyoung-Ho
Son In-Ja
Lee Hye-Sook
|
|
|
Abstract
|
|
|
Voriconazole is a novel wide-spectrum triazole antifungal agent active against Aspergillus, Candida, Fusarium, and Scedosporium, both in vitro and in clinical infections. This study was performed to evaluate the use of voriconazole by the criteria modified from IDSA and anufacturer’s guideline and conducted through retrospective chart review of fifty seven inpatients who received voriconazole in Seoul National University Hospital from January 2006 to June 2008.
The justification of use showed high appropriate rate (87.8%). In analysis of critical indicators, the appropriateness of initial and maintenance dosage of voriconazole accounted for 87.7% and 91.0%. Duration of therapy was proved to be appropriate for 46.7% of patients. Rigorous attempts to correct potassium, magnesium, and calcium were made for 52.8% before starting voriconazole. Liver function tests were evaluated at the start of and during the course of voriconazole therapy
for 56.1% and 86%. There is no coadministration of voriconazole with rifampicin, ritonavir, carbamazepine, or Phenobarbital. The complications occurred in 24 cases including hepatotoxicity(10 cases), visual disturbances(8 cases), nausea(2 cases), drowsy mentality(2 case), tachycardia(1 case), skin rash(1 case) and cough(1 case). At the end of voriconazole therapy, there were successful outcome in 52.8% of the patients. The survival rate was 65%.
|
|
|
KEYWORD
|
|
|
Voriconazole, Drug use evaluation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|